The current study aims to assess the HemoControl prescription in On-Line Hemodiafiltration treatment.
Hemodiafiltration (HDF) is a dialysis technique that allows the removal of high molecular weight toxic solutes exploiting the convective transport through the dialyzer membrane: at the same time, the HDF has a positive impact on the systemic hemodynamic, ameliorating in this way the tolerance of the treatment. Unfortunately, also the HDF therapy can be not well tolerated, introducing in the patients serious hypovolemia during the removal of the body water accumulated in the interdialytic period. The HemoControl system, automatically controlling the relative blood volume change of the patient, avoids the onset of the hypovolemia. Today the HemoControl system can be used only during conventional hemodialysis treatments; the objective of this study is to combine the advantages of the intradialytic hemodynamic stabilization achievable by means of HemoControl with the inherent advantages, both of depurative and cardiovascular kind, typical of the Hemodiafiltration technique.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
7
Software versions: Control Product: 8.06.01KA. Study Product: 8.06.01B\_HC01
Policlinico Sant'Orsola Malpighi
Bologna, (BO), Italy
Sodium mass balance
* to determine whether the same HemoControl prescription is usable in On-Line Hemodiafiltration (HDF) and hemodialysis (HD) treatments and, if not, * to assess the existence of a proper HemoControl prescription in On-Line Hemodiafiltration (HDF) treatment.
Time frame: during dialysis treatment within 18 weeks
blood pressure
difference between the pre-treatment systolic and diastolic blood pressures in On-Line Hemodiafiltration (HDF) and hemodialysis (HD) with respect to the control treatments
Time frame: Pre-dialytic within 18 weeks
thirst perception
Average difference between the thirst score reported by the patient during On-Line Hemodiafiltration (HDF) and hemodialysis (HD) treatments with respect to the score reported during the control treatments
Time frame: during dialysis within 18 weeks
weight gain
difference between the interdialytic weight gain in On-Line Hemodiafiltration (HDF) and hemodialysis (HD) treatments with respect to the control treatment
Time frame: between dialysis treatments within 18 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.